The improved O2 consumption in the kidneys may explain the long-term beneficial renal effects seen with SGLT2 inhibitors both in randomized trials and in observational studies, where the risk of AKI was reduced rather than increased after SGLT2 inhibition. This evidence concerns the gene SLC5A2 and acute kidney injury.